Transcatheter aortic valve replacement (TAVR) has become the dominant treatment modality for symptomatic severe aortic stenosis (AS), regardless of the surgical-risk. The clinical trials that led to the approval of TAVR for the treatment of symptomatic severe AS excluded patients with significant involvement of other cardiac valves. Multivalvular heart disease with significant involvement of more than one valve type is frequently encountered in patients referred for TAVR in real-world practice [ 1 ]. With the ongoing clinical trials of transcatheter mitral valve replacement (TMVR) with dedicated devices, and the recent approval of transcatheter tricuspid valve repair and replacement for the treatment of tricuspid regurgitation, there is renewed interest in studying the prevalence and clinical impact of multivalvular heart disease in the TAVR population.